Copy link
Export CSV
Cite this view
HANK Price Transparency. (n.d.).
Y90 ibritumomab, rx (HCPCS A954300) by State .
PPMan price-transparency data, derived from CMS-required hospital MRFs.
Retrieved June 28, 2026 , from http://ppman.hank.ai/transparency/procedure/A954300/by-state?code_type=HCPCS
“Y90 ibritumomab, rx (HCPCS A954300) by State.” HANK Price Transparency ,
http://ppman.hank.ai/transparency/procedure/A954300/by-state?code_type=HCPCS. Accessed
June 28, 2026 .
“Y90 ibritumomab, rx (HCPCS A954300) by State,” HANK Price Transparency ,
accessed June 28, 2026 ,
http://ppman.hank.ai/transparency/procedure/A954300/by-state?code_type=HCPCS.
Source: PPMan price-transparency data, derived from CMS-required hospital
machine-readable files (45 CFR 180). See
methodology .
Print / Save PDF
HCPCS · across United States
A954300 — Y90 Ibritumomab, Rx
State-by-state median negotiated rates. Lower bars are cheaper states; the
range bar shows the IQR (25th to 75th percentile within each state).
$71,875
National median
$71,875 – $193,837
IQR (p25 – p75)
8
hospitals filing
5
states
Median negotiated rate, by state
Ranked by typical (median) negotiated price. Hover for state-level IQR.
Median negotiated rate by state for A954300 (HCPCS), with interquartile range
State Median p25 p75
NV $208,685 $208,685 $208,685
AR $193,837 $193,837 $193,837
NY $71,875 $71,875 $71,875
CT $70,390 $70,390 $70,390
FL $61,523 $61,523 $61,523